Blueprint Medicines Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 649

Employees

  • Stock Symbol
  • BPMC

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $93.94
  • (As of Friday Closing)

Blueprint Medicines General Information

Description

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Contact Information

Formerly Known As
Hoyle Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 45 Sidney Street
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 45 Sidney Street
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Blueprint Medicines Stock Performance

As of 14-Feb-2025, Blueprint Medicines’s stock price is $93.94. Its current market cap is $6B with 63.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$93.94 $95.19 $80.42 - $121.90 $6B 63.9M 832K -$1.07

Blueprint Medicines Financials Summary

As of 31-Dec-2024, Blueprint Medicines has a trailing 12-month revenue of $509M.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 5,278,047 5,278,047 5,228,290 1,728,175
Revenue 508,824 508,824 249,380 204,036
EBITDA (21,421) (21,421) (475,558) (523,779)
Net Income (67,089) (67,089) (506,984) (557,517)
Total Assets 1,179,813 1,179,813 1,049,250 1,349,902
Total Debt 469,106 469,106 332,497 242,451
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Blueprint Medicines Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Blueprint Medicines‘s full profile, request access.

Request a free trial

Blueprint Medicines Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Blueprint Medicines‘s full profile, request access.

Request a free trial

Blueprint Medicines Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allerg
Drug Discovery
Cambridge, MA
649 As of 2024

San Carlos, CA
 

Hayward, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Blueprint Medicines Competitors (92)

One of Blueprint Medicines’s 92 competitors is Allakos, a Formerly VC-backed company based in San Carlos, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Allakos Formerly VC-backed San Carlos, CA
Arcus Biosciences Formerly VC-backed Hayward, CA
AB Science Formerly Accelerator/Incubator backed Paris, France
Nektar Therapeutics Formerly VC-backed San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 92 competitors. Get the full list »

Blueprint Medicines Patents

Blueprint Medicines Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240382493-A1 Methods for treating systemic mastocytosis and gastrointestinal stromal tumors Pending 18-May-2023
US-20240262826-A1 Wild type kit inhibitors Pending 30-Nov-2022
AU-2023265064-A1 Salt and crystal forms of an epidermal growth factor receptor inhibitor Pending 04-May-2022
AU-2023255386-A1 Kit inhibitors Pending 19-Apr-2022
AU-2023250382-A1 Egfr inhibitors Pending 05-Apr-2022 C07D401/14
To view Blueprint Medicines’s complete patent history, request access »

Blueprint Medicines Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Blueprint Medicines Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Blueprint Medicines‘s full profile, request access.

Request a free trial

Blueprint Medicines Investments & Acquisitions (2)

Blueprint Medicines’s most recent deal was a Early Stage VC with IDRx for . The deal was made on 28-Apr-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
IDRx 28-Apr-2022 Early Stage VC Drug Discovery
Lengo Therapeutics 30-Dec-2021 Merger/Acquisition Drug Discovery
To view Blueprint Medicines’s complete investments and acquisitions history, request access »

Blueprint Medicines ESG

Risk Overview

Risk Rating

Updated December, 21, 2023

22.33 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Biotechnology

Subindustry

of 368

Rank

Percentile

To view Blueprint Medicines’s complete esg history, request access »

Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Blueprint Medicines (US Rights of Gavreto)

Blueprint Medicines FAQs

  • When was Blueprint Medicines founded?

    Blueprint Medicines was founded in 2008.

  • Where is Blueprint Medicines headquartered?

    Blueprint Medicines is headquartered in Cambridge, MA.

  • What is the size of Blueprint Medicines?

    Blueprint Medicines has 649 total employees.

  • What industry is Blueprint Medicines in?

    Blueprint Medicines’s primary industry is Drug Discovery.

  • Is Blueprint Medicines a private or public company?

    Blueprint Medicines is a Public company.

  • What is Blueprint Medicines’s stock symbol?

    The ticker symbol for Blueprint Medicines is BPMC.

  • What is the current stock price of Blueprint Medicines?

    As of 14-Feb-2025 the stock price of Blueprint Medicines is $93.94.

  • What is the current market cap of Blueprint Medicines?

    The current market capitalization of Blueprint Medicines is $6B.

  • What is Blueprint Medicines’s current revenue?

    The trailing twelve month revenue for Blueprint Medicines is $509M.

  • Who are Blueprint Medicines’s competitors?

    Allakos, Arcus Biosciences, AB Science, Nektar Therapeutics, and Adaptimmune Therapeutics are some of the 92 competitors of Blueprint Medicines.

  • What is Blueprint Medicines’s annual earnings per share (EPS)?

    Blueprint Medicines’s EPS for 12 months was -$1.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »